Protagonist Therapeutics' CEO on its hepcidin memetic at #ASH23 and oral IL23 program in I&I
Dinesh Patel describes the science behind Protagonist's polycythemia vera program and how the company is developing oral peptides, starting with IL23.
Also look for unique social pages for BiotechTV U.
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
​
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
​
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
​
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A